Device Trial Radar · NCT07866768
CMN LIFU for Enhanced Amyloid Reduction (CLEAR Study)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Attune Neurosciences Inc; Gates Ventures
- First posted
- Oct 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if a wearable ultrasound device, called ATTN201, is safe and easy to use. The study is for adults ages 65 and older who have mild cognitive impairment (MCI) and a buildup of a protein called amyloid in the brain. Amyloid buildup is an early sign of Alzheimer's disease. The ATTN201 device sends low-intensity sound waves to a deep area of the brain that helps control sleep. The aim is to boost deep-sleep brain waves. These brain waves may help the brain clear away waste, including amyloid. The main questions it aims to answer are: 1. What, if any, issues do participants have when using the ATTN201 device? 2. Can participants complete the full study schedule? Researchers will compare focused ultrasound to unfocused ultrasound. Unfocused ultrasound is a look-alike treatment. It feels and sounds the same but is not aimed at the brain target. The comparison will show if the focused treatment changes sleep brain waves, blood markers of Alzheimer's disease, or memory and thinking. Participants will: * Visit the study site for memory and thinking tests, blood draws, a health check, and MRI scans of the brain * Record their sleep at home for at least 5 days with a sleep diary, a watch-like sensor, and a headband that measures brain waves * Be assigned by chance to focused or unfocused ultrasound * Take part in 10 nap sessions over 2 weeks while wearing the device, at the study site or at home * Return for a final visit to repeat the first tests, and may return for an optional visit 3 months later
Conditions
- Alzheimer's Disease (AD)
- Mild Cognitive Impairment (MCI)
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
ATTN201 Focused Ultrasound to the CMNDevice
Low-intensity focused ultrasound delivered to the centromedian nucleus of the thalamus by the investigational ATTN201 head-worn device.
ATTN201 Unfocused UltrasoundDevice
Unfocused ultrasound delivered by the same device, serving as the control condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, Severity, and Relatedness of Adverse Events and Serious Adverse EventsTime frame: From informed consent through the 3-month follow-up visit (up to ~5 months)
- Incidence of New Clinically Significant Findings on Post-Treatment Safety MRITime frame: From baseline through the post-treatment (~Week 5)
- Study completion rate and adherence to scheduled study proceduresTime frame: From baseline through the post-treatment (~Week 5)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.